Report cover image

Global HIV and AIDS Vaccine Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 197 Pages
SKU # APRC20282645

Description

Summary

According to APO Research, The global HIV and AIDS Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for HIV and AIDS Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for HIV and AIDS Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for HIV and AIDS Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for HIV and AIDS Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of HIV and AIDS Vaccine include HKUMed, Sanofi-Pasteur, Johnson and Johnson (Janssen), IAVI, Uvax Bio and AELIX Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for HIV and AIDS Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of HIV and AIDS Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for HIV and AIDS Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the HIV and AIDS Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global HIV and AIDS Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for HIV and AIDS Vaccine sales, projected growth trends, production technology, application and end-user industry.

HIV and AIDS Vaccine Segment by Company

HKUMed
Sanofi-Pasteur
Johnson and Johnson (Janssen)
IAVI
Uvax Bio
AELIX Therapeutics
HIV and AIDS Vaccine Segment by Type

Preventive Vaccine
Therapeutic Vaccine
HIV and AIDS Vaccine Segment by Application

Viral Vector Vaccines
Nucleic Acid Vaccines (including mRNA Vaccines)
Recombinant Protein Vaccines
Other Vaccines
HIV and AIDS Vaccine Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV and AIDS Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of HIV and AIDS Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV and AIDS Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of HIV and AIDS Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of HIV and AIDS Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HIV and AIDS Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 HIV and AIDS Vaccine Market by Type
1.2.1 Global HIV and AIDS Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Preventive Vaccine
1.2.3 Therapeutic Vaccine
1.3 HIV and AIDS Vaccine Market by Application
1.3.1 Global HIV and AIDS Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Viral Vector Vaccines
1.3.3 Nucleic Acid Vaccines (including mRNA Vaccines)
1.3.4 Recombinant Protein Vaccines
1.3.5 Other Vaccines
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 HIV and AIDS Vaccine Market Dynamics
2.1 HIV and AIDS Vaccine Industry Trends
2.2 HIV and AIDS Vaccine Industry Drivers
2.3 HIV and AIDS Vaccine Industry Opportunities and Challenges
2.4 HIV and AIDS Vaccine Industry Restraints
3 Global Market Growth Prospects
3.1 Global HIV and AIDS Vaccine Revenue Estimates and Forecasts (2020-2031)
3.2 Global HIV and AIDS Vaccine Revenue by Region
3.2.1 Global HIV and AIDS Vaccine Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global HIV and AIDS Vaccine Revenue by Region (2020-2025)
3.2.3 Global HIV and AIDS Vaccine Revenue by Region (2026-2031)
3.2.4 Global HIV and AIDS Vaccine Revenue Market Share by Region (2020-2031)
3.3 Global HIV and AIDS Vaccine Sales Estimates and Forecasts 2020-2031
3.4 Global HIV and AIDS Vaccine Sales by Region
3.4.1 Global HIV and AIDS Vaccine Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global HIV and AIDS Vaccine Sales by Region (2020-2025)
3.4.3 Global HIV and AIDS Vaccine Sales by Region (2026-2031)
3.4.4 Global HIV and AIDS Vaccine Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global HIV and AIDS Vaccine Revenue by Manufacturers
4.1.1 Global HIV and AIDS Vaccine Revenue by Manufacturers (2020-2025)
4.1.2 Global HIV and AIDS Vaccine Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global HIV and AIDS Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global HIV and AIDS Vaccine Sales by Manufacturers
4.2.1 Global HIV and AIDS Vaccine Sales by Manufacturers (2020-2025)
4.2.2 Global HIV and AIDS Vaccine Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global HIV and AIDS Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global HIV and AIDS Vaccine Sales Price by Manufacturers (2020-2025)
4.4 Global HIV and AIDS Vaccine Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global HIV and AIDS Vaccine Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global HIV and AIDS Vaccine Manufacturers, Product Type & Application
4.7 Global HIV and AIDS Vaccine Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global HIV and AIDS Vaccine Market CR5 and HHI
4.8.2 2024 HIV and AIDS Vaccine Tier 1, Tier 2, and Tier 3
5 HIV and AIDS Vaccine Market by Type
5.1 Global HIV and AIDS Vaccine Revenue by Type
5.1.1 Global HIV and AIDS Vaccine Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global HIV and AIDS Vaccine Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global HIV and AIDS Vaccine Revenue Market Share by Type (2020-2031)
5.2 Global HIV and AIDS Vaccine Sales by Type
5.2.1 Global HIV and AIDS Vaccine Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global HIV and AIDS Vaccine Sales by Type (2020-2031) & (K Units)
5.2.3 Global HIV and AIDS Vaccine Sales Market Share by Type (2020-2031)
5.3 Global HIV and AIDS Vaccine Price by Type
6 HIV and AIDS Vaccine Market by Application
6.1 Global HIV and AIDS Vaccine Revenue by Application
6.1.1 Global HIV and AIDS Vaccine Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global HIV and AIDS Vaccine Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global HIV and AIDS Vaccine Revenue Market Share by Application (2020-2031)
6.2 Global HIV and AIDS Vaccine Sales by Application
6.2.1 Global HIV and AIDS Vaccine Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global HIV and AIDS Vaccine Sales by Application (2020-2031) & (K Units)
6.2.3 Global HIV and AIDS Vaccine Sales Market Share by Application (2020-2031)
6.3 Global HIV and AIDS Vaccine Price by Application
7 Company Profiles
7.1 HKUMed
7.1.1 HKUMed Comapny Information
7.1.2 HKUMed Business Overview
7.1.3 HKUMed HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 HKUMed HIV and AIDS Vaccine Product Portfolio
7.1.5 HKUMed Recent Developments
7.2 Sanofi-Pasteur
7.2.1 Sanofi-Pasteur Comapny Information
7.2.2 Sanofi-Pasteur Business Overview
7.2.3 Sanofi-Pasteur HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Sanofi-Pasteur HIV and AIDS Vaccine Product Portfolio
7.2.5 Sanofi-Pasteur Recent Developments
7.3 Johnson and Johnson (Janssen)
7.3.1 Johnson and Johnson (Janssen) Comapny Information
7.3.2 Johnson and Johnson (Janssen) Business Overview
7.3.3 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Portfolio
7.3.5 Johnson and Johnson (Janssen) Recent Developments
7.4 IAVI
7.4.1 IAVI Comapny Information
7.4.2 IAVI Business Overview
7.4.3 IAVI HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 IAVI HIV and AIDS Vaccine Product Portfolio
7.4.5 IAVI Recent Developments
7.5 Uvax Bio
7.5.1 Uvax Bio Comapny Information
7.5.2 Uvax Bio Business Overview
7.5.3 Uvax Bio HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Uvax Bio HIV and AIDS Vaccine Product Portfolio
7.5.5 Uvax Bio Recent Developments
7.6 AELIX Therapeutics
7.6.1 AELIX Therapeutics Comapny Information
7.6.2 AELIX Therapeutics Business Overview
7.6.3 AELIX Therapeutics HIV and AIDS Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 AELIX Therapeutics HIV and AIDS Vaccine Product Portfolio
7.6.5 AELIX Therapeutics Recent Developments
8 North America
8.1 North America HIV and AIDS Vaccine Market Size by Type
8.1.1 North America HIV and AIDS Vaccine Revenue by Type (2020-2031)
8.1.2 North America HIV and AIDS Vaccine Sales by Type (2020-2031)
8.1.3 North America HIV and AIDS Vaccine Price by Type (2020-2031)
8.2 North America HIV and AIDS Vaccine Market Size by Application
8.2.1 North America HIV and AIDS Vaccine Revenue by Application (2020-2031)
8.2.2 North America HIV and AIDS Vaccine Sales by Application (2020-2031)
8.2.3 North America HIV and AIDS Vaccine Price by Application (2020-2031)
8.3 North America HIV and AIDS Vaccine Market Size by Country
8.3.1 North America HIV and AIDS Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America HIV and AIDS Vaccine Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America HIV and AIDS Vaccine Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
8.3.6 Mexico
9 Europe
9.1 Europe HIV and AIDS Vaccine Market Size by Type
9.1.1 Europe HIV and AIDS Vaccine Revenue by Type (2020-2031)
9.1.2 Europe HIV and AIDS Vaccine Sales by Type (2020-2031)
9.1.3 Europe HIV and AIDS Vaccine Price by Type (2020-2031)
9.2 Europe HIV and AIDS Vaccine Market Size by Application
9.2.1 Europe HIV and AIDS Vaccine Revenue by Application (2020-2031)
9.2.2 Europe HIV and AIDS Vaccine Sales by Application (2020-2031)
9.2.3 Europe HIV and AIDS Vaccine Price by Application (2020-2031)
9.3 Europe HIV and AIDS Vaccine Market Size by Country
9.3.1 Europe HIV and AIDS Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe HIV and AIDS Vaccine Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe HIV and AIDS Vaccine Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
9.3.9 Spain
9.3.10 Netherlands
10 China
10.1 China HIV and AIDS Vaccine Market Size by Type
10.1.1 China HIV and AIDS Vaccine Revenue by Type (2020-2031)
10.1.2 China HIV and AIDS Vaccine Sales by Type (2020-2031)
10.1.3 China HIV and AIDS Vaccine Price by Type (2020-2031)
10.2 China HIV and AIDS Vaccine Market Size by Application
10.2.1 China HIV and AIDS Vaccine Revenue by Application (2020-2031)
10.2.2 China HIV and AIDS Vaccine Sales by Application (2020-2031)
10.2.3 China HIV and AIDS Vaccine Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia HIV and AIDS Vaccine Market Size by Type
11.1.1 Asia HIV and AIDS Vaccine Revenue by Type (2020-2031)
11.1.2 Asia HIV and AIDS Vaccine Sales by Type (2020-2031)
11.1.3 Asia HIV and AIDS Vaccine Price by Type (2020-2031)
11.2 Asia HIV and AIDS Vaccine Market Size by Application
11.2.1 Asia HIV and AIDS Vaccine Revenue by Application (2020-2031)
11.2.2 Asia HIV and AIDS Vaccine Sales by Application (2020-2031)
11.2.3 Asia HIV and AIDS Vaccine Price by Application (2020-2031)
11.3 Asia HIV and AIDS Vaccine Market Size by Country
11.3.1 Asia HIV and AIDS Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia HIV and AIDS Vaccine Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia HIV and AIDS Vaccine Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA HIV and AIDS Vaccine Market Size by Type
12.1.1 SAMEA HIV and AIDS Vaccine Revenue by Type (2020-2031)
12.1.2 SAMEA HIV and AIDS Vaccine Sales by Type (2020-2031)
12.1.3 SAMEA HIV and AIDS Vaccine Price by Type (2020-2031)
12.2 SAMEA HIV and AIDS Vaccine Market Size by Application
12.2.1 SAMEA HIV and AIDS Vaccine Revenue by Application (2020-2031)
12.2.2 SAMEA HIV and AIDS Vaccine Sales by Application (2020-2031)
12.2.3 SAMEA HIV and AIDS Vaccine Price by Application (2020-2031)
12.3 SAMEA HIV and AIDS Vaccine Market Size by Country
12.3.1 SAMEA HIV and AIDS Vaccine Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA HIV and AIDS Vaccine Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA HIV and AIDS Vaccine Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 HIV and AIDS Vaccine Value Chain Analysis
13.1.1 HIV and AIDS Vaccine Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 HIV and AIDS Vaccine Production Mode & Process
13.2 HIV and AIDS Vaccine Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 HIV and AIDS Vaccine Distributors
13.2.3 HIV and AIDS Vaccine Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.